JP2006506348A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006506348A5 JP2006506348A5 JP2004535155A JP2004535155A JP2006506348A5 JP 2006506348 A5 JP2006506348 A5 JP 2006506348A5 JP 2004535155 A JP2004535155 A JP 2004535155A JP 2004535155 A JP2004535155 A JP 2004535155A JP 2006506348 A5 JP2006506348 A5 JP 2006506348A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- substituted
- aryl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002193 Pain Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- 230000008450 motivation Effects 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- -1 (C 1-6- Alkyl) -aryl Chemical group 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 3
- 150000001733 carboxylic acid esters Chemical class 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims 2
- SLLFVLKNXABYGI-UHFFFAOYSA-N 1,2,3-benzoxadiazole Chemical compound C1=CC=C2ON=NC2=C1 SLLFVLKNXABYGI-UHFFFAOYSA-N 0.000 claims 1
- 125000001847 2-phenylcyclopropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1([H])C([H])([H])C1([H])* 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims 1
- 150000003852 triazoles Chemical class 0.000 claims 1
- 239000000126 substance Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 239000000935 antidepressant agent Substances 0.000 description 4
- RLQZIECDMISZHS-UHFFFAOYSA-N 2-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1 RLQZIECDMISZHS-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 208000000094 Chronic Pain Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000003001 depressive effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000017194 Affective disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 238000011785 NMRI mouse Methods 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10240818A DE10240818A1 (de) | 2002-08-30 | 2002-08-30 | Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate |
| PCT/EP2003/009390 WO2004024725A1 (de) | 2002-08-30 | 2003-08-25 | 2-pyrrolidin-2-yl-[1,3,4]-oxadiazol-derivate und ihre verwendung als antidepressiva |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006506348A JP2006506348A (ja) | 2006-02-23 |
| JP2006506348A5 true JP2006506348A5 (enExample) | 2010-05-27 |
Family
ID=31983895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004535155A Pending JP2006506348A (ja) | 2002-08-30 | 2003-08-25 | ２−ピロリジン−２−イル−［１，３，４］−オキサジアゾール−誘導体及びこれを抗うつ剤として使用する方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7105538B2 (enExample) |
| EP (1) | EP1532141B1 (enExample) |
| JP (1) | JP2006506348A (enExample) |
| CN (1) | CN100390168C (enExample) |
| AR (1) | AR041093A1 (enExample) |
| AT (1) | ATE484503T1 (enExample) |
| CA (1) | CA2497078A1 (enExample) |
| CY (1) | CY1110913T1 (enExample) |
| DE (2) | DE10240818A1 (enExample) |
| DK (1) | DK1532141T3 (enExample) |
| ES (1) | ES2351119T3 (enExample) |
| MX (1) | MXPA05002298A (enExample) |
| PE (1) | PE20040983A1 (enExample) |
| PL (1) | PL375627A1 (enExample) |
| PT (1) | PT1532141E (enExample) |
| RU (1) | RU2324694C2 (enExample) |
| SI (1) | SI1532141T1 (enExample) |
| WO (1) | WO2004024725A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2291080E (pt) | 2008-05-14 | 2015-10-30 | Scripps Research Inst | Novos modelamodeladores dos recetores da esfingosina fosfato |
| RU2417995C1 (ru) * | 2009-09-21 | 2011-05-10 | Государственное образовательное учреждение высшего профессионального образования "Кубанский государственный технологический университет" (ГОУ ВПО "КубГТУ") | Способ получения 3-(2-замещенных-1,3-оксазол-4-ил)пиридин-2(1н)-онов |
| CN103420998A (zh) * | 2012-05-16 | 2013-12-04 | 苏州爱斯鹏药物研发有限责任公司 | 一种新型噁二唑衍生物的合成方法 |
| DK2855453T3 (en) | 2012-06-04 | 2017-02-06 | Actelion Pharmaceuticals Ltd | Benzimidazol-proline derivatives |
| US10092574B2 (en) | 2012-09-26 | 2018-10-09 | Valorisation-Recherche, Limited Partnership | Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof |
| BR112015007516A2 (pt) * | 2012-10-10 | 2017-07-04 | Actelion Pharmaceuticals Ltd | antagonistas do receptor de orexina que são derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)- pirrolidin-1-il]-metanona |
| CN105051040A (zh) * | 2013-03-12 | 2015-11-11 | 埃科特莱茵药品有限公司 | 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物 |
| CN103333165B (zh) * | 2013-07-01 | 2016-02-24 | 河南理工大学 | 2-苯基-5-(3,4-二甲基)吡咯基-1,3,4-噁二唑及制备方法 |
| SI3077391T1 (sl) | 2013-12-04 | 2018-11-30 | Idorsia Pharmaceuticals Ltd | Uporaba benzimidazol-prolinskih derivatov |
| CN111978311B (zh) * | 2019-05-21 | 2024-05-31 | 中国科学院上海有机化学研究所 | 一类细胞程序性坏死抑制剂及其制备方法和用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2215949B1 (enExample) * | 1973-02-01 | 1976-07-02 | Delalande Sa | |
| US4784998A (en) * | 1987-04-06 | 1988-11-15 | Bristol-Myers Company | 1,3,4-oxadiazole pyschotropic compounds |
| DE19643037A1 (de) * | 1996-10-18 | 1998-04-23 | Boehringer Ingelheim Kg | Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel |
| US5965537A (en) * | 1997-03-10 | 1999-10-12 | Basf Aktiengesellschaft | Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus |
| CN1382140A (zh) * | 1999-07-09 | 2002-11-27 | 奥索-麦克尼尔药品公司 | 具有神经营养活性的吡咯烷和哌啶、以及含有它们的相关组合物 |
| JP2001247569A (ja) * | 1999-08-12 | 2001-09-11 | Japan Tobacco Inc | ピロリジン誘導体又はピペリジン誘導体及びその医薬用途 |
| US6589978B2 (en) * | 2000-06-30 | 2003-07-08 | Hoffman-La Roche Inc. | 1-sulfonyl pyrrolidine derivatives |
-
2002
- 2002-08-30 DE DE10240818A patent/DE10240818A1/de not_active Withdrawn
-
2003
- 2003-08-25 RU RU2005109164/04A patent/RU2324694C2/ru not_active IP Right Cessation
- 2003-08-25 EP EP03794933A patent/EP1532141B1/de not_active Expired - Lifetime
- 2003-08-25 DK DK03794933.6T patent/DK1532141T3/da active
- 2003-08-25 WO PCT/EP2003/009390 patent/WO2004024725A1/de not_active Ceased
- 2003-08-25 CN CNB038201976A patent/CN100390168C/zh not_active Expired - Fee Related
- 2003-08-25 PT PT03794933T patent/PT1532141E/pt unknown
- 2003-08-25 CA CA002497078A patent/CA2497078A1/en not_active Abandoned
- 2003-08-25 ES ES03794933T patent/ES2351119T3/es not_active Expired - Lifetime
- 2003-08-25 PL PL03375627A patent/PL375627A1/xx not_active Application Discontinuation
- 2003-08-25 JP JP2004535155A patent/JP2006506348A/ja active Pending
- 2003-08-25 DE DE50313185T patent/DE50313185D1/de not_active Expired - Lifetime
- 2003-08-25 MX MXPA05002298A patent/MXPA05002298A/es active IP Right Grant
- 2003-08-25 AT AT03794933T patent/ATE484503T1/de active
- 2003-08-25 SI SI200331896T patent/SI1532141T1/sl unknown
- 2003-08-28 PE PE2003000883A patent/PE20040983A1/es not_active Application Discontinuation
- 2003-08-29 AR ARP030103137A patent/AR041093A1/es unknown
-
2005
- 2005-02-28 US US11/066,981 patent/US7105538B2/en not_active Expired - Fee Related
-
2010
- 2010-11-17 CY CY20101101028T patent/CY1110913T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101772834B1 (ko) | 다환형 화합물 및 이의 사용 방법 | |
| US20130224151A1 (en) | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain | |
| JP2009542702A5 (enExample) | ||
| US20200054594A1 (en) | Pharmaceutical composition containing mor agonist and kor agonist, and uses thereof | |
| JP2021505547A (ja) | 疼痛を治療するための薬物の製造におけるｍｏｒアゴニストと組み合わせたｋｏｒアゴニストの使用 | |
| JP2009542699A5 (enExample) | ||
| RU2009114857A (ru) | Гетероциклические органические соединения | |
| RU2010107284A (ru) | Производные нафтиридина в качестве модуляторов калиевых каналов | |
| JP2013006854A5 (enExample) | ||
| CN101528214A (zh) | 取代的n-酰基苯胺及其使用方法 | |
| JP2018502101A5 (enExample) | ||
| JP2014528464A5 (enExample) | ||
| TW200840573A (en) | Heterocyclic compounds and their methods of use | |
| KR102803160B1 (ko) | sGC 자극제의 고체 형태 | |
| KR20240027769A (ko) | Mnk 억제를 나타내는 스피로사이클릭 피리딘-1,5-디온 및 이의 사용 방법 | |
| JP2009511519A5 (enExample) | ||
| JP2005513017A5 (enExample) | ||
| KR20230004662A (ko) | 1,5-디하이드로-2,4-벤조디아제핀-3-온 유도체 및 이의 응용 | |
| JP2023521237A (ja) | 抗ウイルス１，３－ジ－オキソ－インデン化合物 | |
| WO2021170811A1 (en) | Method of treating eye disease using trpv4 antagonists | |
| JP2022527618A5 (enExample) | ||
| CN108403698A (zh) | 用于治疗细菌感染的方法和组合物 | |
| JP2008538583A5 (enExample) | ||
| US20080293685A1 (en) | Spiro and other derivatives of diamondoids possessing therapeutic activity in the treatment of viral disorders | |
| JP6321274B2 (ja) | トリプル再取込み阻害剤及びそれらの使用方法 |